Leaflet DAKLINZA 60mg film-coated tablets

Product code:
W61011001
Quantity:
28
Indicated for:
chronic hepatitis C
Route of administration:
oral
Substance:
daclatasvir (antiviral)
ATC
J05AX14 — Antiinfectives for systemic use | Direct acting antivirals | Other antivirals

Precautions:

Dose adjustment in renal impairment

Dose adjustment may be needed in kidney disease.

Major drug interactions

This medicine may have important interactions with other medicines.

Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning

Use during pregnancy only on medical advice.

Daclatasvir is an antiviral medication used for the treatment of chronic hepatitis C. It works by inhibiting the NS5A protein, which is essential for the replication of the hepatitis C virus, thereby helping to eliminate the infection.

The medication is taken orally, usually in combination with other antivirals such as sofosbuvir, to enhance treatment effectiveness. It is indicated for various genotypes of the hepatitis C virus.

Side effects may include fatigue, headache, nausea, and insomnia. In rare cases, allergic reactions or other severe side effects may occur. It is important to follow all medical recommendations during treatment.

Consult your doctor to discuss the benefits and risks of treatment with Daclatasvir. Regular monitoring is essential to ensure the success of the therapy.

General data about DAKLINZA 60mg

Substance:
daclatasvir
Date of latest medicines list:
01-01-2019
Product code:
W61011001
Concentration:
60mg
Pharmaceutical form:
film-coated tablets
Quantity:
28
Product type:
Original
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Concentrations available for daclatasvir

  • 30mg
  • 60mg